Adult Retinal Pigment Epithelial Transplantation in Exudative Age-related Macular Degeneration
Overview
Affiliations
Purpose: To improve visual function by retinal pigment epithelial (RPE) cell transplantation and systemic immunosuppression at the time of surgical removal of subfoveal choroidal neovascularization in exudative age-related macular degeneration (AMD).
Design: An interventional case series of RPE transplantation in exudative AMD.
Methods: Twelve patients (one eye only) underwent subfoveal membranectomy with transplantation of a sheet of adult human allogeneic RPE cells at a single institution and were followed for one year. Eligibility criteria included age >60, best-corrected acuity < or =20/63 and subfoveal neovascularization < or =9 disk areas on preoperative fluorescein angiography. All patients were started on triple immunosuppression postoperatively. The primary outcome measure was best-corrected vision, with contrast sensitivity and reading speed as secondary outcome measures.
Results: The best-corrected visual acuity (P = .085), contrast sensitivity (P = .204), and the reading speed (P = .077) did not change significantly at one year compared with preoperative values. Transplants showed no signs of rejection in patients who were able to continue the immunosuppressants for six months. Postoperative surgical complications included cataract progression requiring surgery (three of eight phakic eyes), retinal detachment (three eyes), intraoperative retinal breaks (two eyes), and macular pucker (two eyes). None of the patients developed cystoid macular edema on postoperative fluorescein angiography or postoperative inflammation.
Conclusions: A sheet of adult human allogeneic RPE can be transplanted into the subretinal space in AMD patients at the time of subfoveal membranectomy. Systemic immune suppression appeared to prevent rejection of the transplanted tissue, but did not lead to an improvement in visual function.
Advances in the study of tissue-engineered retinal pigment epithelial cell sheets.
Zhou W, Chai Y, Lu S, Yang Q, Tang L, Zhou D Regen Ther. 2024; 27:419-433.
PMID: 38694444 PMC: 11062139. DOI: 10.1016/j.reth.2024.04.008.
Recent Progress in Retinal Pigment Epithelium Cell-Based Therapy for Retinal Disease.
Klymenko V, Gonzalez Martinez O, Zarbin M Stem Cells Transl Med. 2024; 13(4):317-331.
PMID: 38394392 PMC: 11016854. DOI: 10.1093/stcltm/szae004.
Abedin Zadeh M, Alany R, Satarian L, Shavandi A, Abdullah Almousa M, Brocchini S Pharmaceutics. 2023; 15(5).
PMID: 37242572 PMC: 10224349. DOI: 10.3390/pharmaceutics15051330.
Retinal Pigment Epithelium Transplantation: Past, Present, and Future.
Khan A, Utheim T, Eidet J J Ophthalmic Vis Res. 2023; 17(4):574-580.
PMID: 36620704 PMC: 9806312. DOI: 10.18502/jovr.v17i4.12325.
Raimondi R, Zollet P, De Rosa F, Tsoutsanis P, Stravalaci M, Paulis M Int J Mol Sci. 2022; 23(2).
PMID: 35054869 PMC: 8775975. DOI: 10.3390/ijms23020682.